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Abstract
One cause of cancer mortality is tumor evolution to therapy-resistant disease. First line therapy 
often targets the dominant clone, and drug resistance can emerge from preexisting clones that gain 
fitness through therapy-induced natural selection. Such mutations may be identified using targeted 
sequencing assays by analysis of noise in high-depth data. Here, we develop a comprehensive, 
unbiased model for sequencing error background. We find that noise in sufficiently deep DNA 
sequencing data can be approximated by aggregating negative binomial distributions. Mutations 
with frequencies above noise may have prognostic value. We evaluate our model with simulated 
exponentially expanded populations as well as data from cell line and patient sample dilution 
experiments, demonstrating its utility in prognosticating tumor progression. Our results may have 
the potential to identify significant mutations that can cause recurrence. These results are relevant 
in the pre-treatment clinical setting to determine appropriate therapy and prepare for potential 
recurrence pretreatment.
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1 Introduction
Every extant organism is the result of over three billion years of evolution. Complex 
organisms consist of cells whose functions are regulated by a large number of interconnected 
pathways that ensure cellular, tissue, and organ homeostasis. Cancer is a result of the 
breakdown of this process in a single cell, which results in its unregulated growth. In most 
cases, the immune system is able to detect and eliminate such aberrant cells. Sometimes, 
however, a clone escapes this surveillance and manifests as clinically detectable disease 
[47]. Consequently, most clinically diagnosable tumors are clonal, i.e. they grow clonally 
from a single cell that finds a path to circumvent the body’s defense mechanisms. The 
growing tumor accumulates mutations, most of which have low or no fitness and therefore 
are found at low frequencies, outcompeted by the dominant clone [30].
The clonal expansion process, which underlies genomic diversification within a tumor, was 
first studied by Salvador Luria and Max Delbrück. They designed a simple system of single-
cell organisms to investigate patterns of mutation accumulation. Their rigorous quantitative 
methodology led them to discover that mutations arise randomly and their numbers follow a 
distinct probability distribution [28]. As the cell population in the tumor diversifies, it is able 
to explore the fitness landscape. Studying the dynamics of this genomic heterogeneity can 
yield insight into when the clonal expansion started, how fast the population evolved, and 
whether specific genomic alterations were selected in a particular host or under a treatment 
regimen.
The principal biochemical mechanisms in cancer are often recurrent across tumors in 
different tissues. For example, aberrations leading to unregulated cell growth or inactivation 
of the apoptotic pathway (cell suicide) are common to almost all tumors. Given the limits 
within which cells are regulated, the growing tumor has access to only a finite number of 
pathways that it can alter. As a result, tumors arising from different cells of origin often 
harbor identical genetic mutations, which alter the same pathways, and often have similar 
prognostic consequences [5].
First line therapy drugs target a tumor’s dominant, fastest growing clone. Drug resistance 
often emerges from the rise of preexisting clones that harbor potential driver mutations that 
gain evolutionary fitness via therapy-induced natural selection. It has been shown that the 
presence of drug-resistant sub-clones in the primary tumor prior to therapy may be a strong 
predictor of poor survival, with direct implications for disease management [41,51,44,35]. 
As cancer therapy moves towards individualized treatment, it is important to identify and 
understand the role of such mutations, some of which may have prognostic value. Such 
potentially prognostic mutations are commonly identified using targeted deep sequencing of 
the tumor DNA in clinical settings, and their sensitive detection relies on the accurate 
analysis of background noise, specifically DNA sequencing errors.
Studying the evolution of chronic lymphocytic leukemia (CLL) under therapy is an 
illuminating example of these approaches [23,24]. CLL is the most common leukemia in 
adults and its clinical course ranges from asymptomatic disease that never requires therapy 
to rapidly progressive disease that requires intensive treatment. Genomic alterations in CLL 
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follow a time ordered process [52]. Patients who harbor genomic defects in the TP53 gene, 
which regulates many pathways including the cell suicide or apoptotic pathway, are 
considered at high risk of failing conventional therapies [42]. Such patients are good 
candidates for stem cell transplant or new gene-specific therapeutics [46,2]. The presence of 
such secondary mutations in genes such as TP53 is often assessed using traditional Sanger 
sequencing that only provides sufficient power to detect mutations present in at least 20% of 
leukemia cells [39]. To assess the presence of TP53 prognostic mutations at lower 
abundances in newly diagnosed CLL patients, we used deep sequencing and evaluated 
thousands of leukemia cells and identified small TP53 mutations that were missed by 
traditional methods such as Sanger sequencing [41]. We found that TP53 mutated sub-clones 
identified before treatment became the predominant population at the time of CLL relapse, 
as a result of therapy induced selection pressure. These results suggest that tumors harboring 
small TP53 mutations have the same clinical phenotype and risk of failing therapy as those 
with TP53 defects in the dominant clone [41,34], and their early detection is essential for the 
identification and management of high-risk CLL patients [12].
These results are also pertinent to other hematological malignancies where the presence of 
leukemia-associated mutations in remission is associated with significantly increased risk of 
relapse and poor survival [38,44]. These data lead to the conclusion that it is imperative to 
identify alterations that induce therapeutic resistance in leukemia patients in the early stages 
of disease in order to properly guide individualized therapy with the goal of preventing 
disease relapse. However, the detection of mutations at low allele frequencies (e.g., 1 
mutation in 10,000 cells) is hindered by the lack of a precise model of noise in diagnostic 
sequencing assays.
Targeted sequencing is the most commonly used method to track prognostic markers in both 
clinical and basic research applications [10]. However, finding such mutations in sequencing 
reads is often confounded by misreading a base in the sequencing instrument or mis-
incorporation of DNA bases (nucleotides) during library enrichment by polymerase chain 
reaction (PCR) amplification cycles. More accurate sequencing protocols, which perform 
overlapping reads of the same genomic DNA region, allows the merging of such reads for 
improved accuracy. This facilitates correcting errors accumulated in the sequencer, while 
leaving uncorrected PCR errors that arise during library preparation steps [4,53,17].
The challenge in identifying potentially functional sub-dominant mutations is to determine 
the sensitivity thresholds of sequencing platforms, i.e. the depths above which PCR errors 
happen with a probability below a statistical cut-off. Such thresholds can be estimated by 
hypothesizing that all variants are due to errors and using deviations from this null 
hypothesis to indicate the presence of true variants. This can sometimes be confounded by 
the fact that different sequencing errors occur at different rates [6,3,11], as the mechanism of 
nucleotide misincorporations during PCR amplification by polymerase molecules is the 
same is the rise of spontaneous mutations that drive Darwinian variation. Hence a single 
threshold cannot comprehensively test the significance of all variants. As a result, more 
sophisticated statistical modeling of the background error distribution is necessary.
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To model background error one may use different types of error distributions: (i) a single or 
a linear combination of Luria-Delbrück distributions, characterizing the expected number of 
spontaneous nucleotide misincorporations, when PCR error rate is assumed to be constant 
[20]; (ii) the negative binomial distribution, describing the depth distribution of clones after 
PCR amplification through a Poisson-Gamma mixture model [36]; and iii) the beta-binomial 
distribution, suitable for Bayesian models, where error rates are assumed to follow the Beta 
distribution [25].
The Luria-Delbrück distribution, which has been demonstrated to accurately describe 
mutagenesis by bacterial polymerases using high-depth error-corrected sequencing [17], is 
expected to better model the long tail of the error depths. However, empirical analysis has 
shown that the negative binomial distribution gives the best fit to the observed error depths 
based on goodness-of-fit log-likelihood [41]. The beta-binomial distribution, in conjunction 
with multiple filtering criteria based on normal control DNA samples, has also been 
proposed for somatic mutation detection from cancer genomes [27,8,43,9]. Finally, 
empirical Bayes methods that establish prior distributions based on observations in the data 
have also been used for detection and genotyping variants and comparing allele frequencies 
across different samples for both tumor and viral populations [33,48,21,14].
In this manuscript, we revisit this problem and provide a comprehensive model that 
illustrates how aggregate negative binomial distributions describe PCR error depths in ultra-
deep targeted sequencing. We test our model with in silico as well as cell line and patient 
dilution experiments, and propose a highly sensitive, mutation-specific approach to detect 
true mutations, without the need for control data from un-mutated (wild type) normal tissue 
DNA.
2 Methods
Derivation of the error depth distribution
Here, we will only be discussing the distribution of low frequency errors in deep DNA 
sequencing analysis of tumor samples. Let us assume an experiment in which S independent 
tissue samples are subjected to ultra-deep sequencing. DNA sequencing of tumor samples 
produces strings of nucleotides (A, C, G, and T) of 100–200 base-pair length that correspond 
to the DNA sequences of different sections of the genome in the tumor sample. These 
sequences of DNA reads are mapped to a “reference” genome and deviations/mismatches 
are identified as potential mutations. Ideally, the reference sequence is the sequence from the 
patient’s “germ-line”, usually obtained from blood or some other tissue with normal cells. 
The sequencing read depth is the average number of reads that map to the same locus 
(section of the genome). At a nucleotide, three potential single base substitutions can occur: 
A (adenine) → C, G, T, or C (cytosine) → A, G, T, or G (guanine) → A, C, T, or T 
(thymine) → A, C, G. Alternately, there might be an insertion (addition of one or more A, 
C, G, T nucleotides) or a deletion (loss of A, C, G, T nucleotides). All of these will 
henceforth be referred to as variants. We want to derive the posterior probability distribution 
for these variants, assuming they are stochastic, i.e. they represent noise (statistical random 
errors).
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Suppose that, at a genomic DNA locus, we see ni such variant reads amongst Ni total reads. 
The distribution of ni follows a binomial distribution, Bino(ni|Ni, θ), where θ is the a priori 
probability of a variant’s occurrence. Let M = ∑i ≠ j
S Ni be the total number of reads across 
samples at that locus and m = ∑i ≠ j
S ni be the total number of variant (erroneous) reads 
across samples at that DNA locus. Then, the posterior predictive p value for having detected 
a true mutation in sample j, given S – 1 other samples, can be obtained from the posterior 
probability distribution:
P(n j ∣ N j, {ni,Ni}) = ∫0
1
Bino(n j ∣ N j, θ) ∏
i ≠ j
Bino(ni ∣ Ni, θ)
∫ 0
1 ∏
i ≠ j
Bino(ni ∣ Ni, θ′)dθ′
dθ′
=
N j
n j
×∫0
1 θ
n j + m(1 − θ)
N j − n j +M − m
∫ 0
1θm(1 − θ)M − mdθ
dθ
=
N j
n j
×
Beta(1 + n j + m, 1 + N j − n j +M − m)
Beta(1 + m, 1 +M − m) ,
where Beta indicates the Beta function. Simplifying the algebra yields the beta-binomial 
distribution,
P(n j ∣ N j,m,M) =
1 +M
1 + N j +M
N j
n j
M
m
N j +M
n j + m
. (1)
Variations of equation (1) have been previously derived for sequencing depths > 100× 
[8,43,9]. Today, it is possible to do ultra-deep sequencing, where Ni > 5,000×. In such cases, 
for low frequency variants, we can assume that ni ≪ Ni. Therefore, we can use Stirling’s 
approximation, and estimate 
Ni
ni
≈
Ni
ni
ni!
. Equation (1) can then be approximated by
P(n j ∣ N j,m,M) =
n j + m
n j
(
N j
N j +M
)
n j
( MN j +M
)
m + 1
, (2)
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which equals NB(n j ∣ 1 + m,
N j
N j +M
), with NB indicating the negative binomial distribution, 
and where 1 + m and 
N j
N j +M
 are its two parameters, which we can interpret as the number of 
detected errors and the a priori probability of success in detecting an error, respectively.
Exponential expansions at varying error rates
An exponentially expanded population is generated through c PCR amplification cycles, 
where each cycle doubles the DNA population. If errors accumulate independently at a rate 
of μ substitutions per site per cycle, the average error depth (i.e. the average number of reads 
harboring errors) is 2cμ. For S such populations, the error depth distribution is described by 
equation (1), or is approximated by a negative binomial distribution, NB(1 + (S − 1)2cμ, 1S ), as 
derived above in equation (2).
It is well known that different types of PCR errors occur at different rates. For example, 
transitions, that exchange two-ring purines (A and G) or one-ring pyrimidines (C and T) are 
more common than transversions, which replace an A or G with one of C or T. Assuming R 
independent rates, the observed number of variants with error depth v, D(v), is given by,
D(v) = ∑
r = 1
R
XrP(v ∣ 2
c, (S − 1)2cμr, (S − 1)2
c)
≈ ∑
r = 1
R
XrNB(v ∣ 1 + (S − 1)2
cμr,
1
S ),
(3)
where Xr represents the number of variants that occur with rate μr. Since error rates are often 
unknown and sequence context dependent, we can alternatively bin the variants based on 
their average error depth across samples and write D(v) as
D(v) = ∑
b = 1
B
XbP(v ∣ 〈N〉, (S − 1)〈v〉b, (S − 1)〈N〉)
≈ ∑
b = 1
B
XbNB(v ∣ 1 + (S − 1)〈v〉b,
1
S ),
(4)
where B is the number of bins, Xb is the number of variants in each bin, and 〈N〉 is the 
average sequencing depth across S samples. It has been shown that the sum of negative 
binomial distributions with equal success probabilities is also a negative binomial 
distribution, though with a random parameter [7, 50]. Thus, the approximation of D(v) in 
equations (3) and (4) with sums of negative binomial distributions that have success 
probability of 1S , suggests empirical observations [41].
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The MATLAB implementation for simulating exponentially expanding populations as well 
as calculating cumulative P using equations (1) and (2) are available at software.khiabanian-
lab.org.
3 Data
In the first experiment, a series of dilutions was generated using the SU-DHL-6 cell line 
(Diffuse Large B-Cell Lymphoma), which carries a heterozygous (one allele altered)TP53-
Y234C missense mutation (one that changes an amino acid in a protein sequence) [32]. The 
cells were serially diluted at (1:10, 1:102, 1:103, 5:104, 1:104, 5:105, and 1:105) by mixing 
the cell line DNA with TP53 wild-type genomic DNA from a healthy donor. The TP53 
mutation locus was sequenced at depths of 10,000× (10K×), 100,000× (100K×), and 
1,000,000× (1M×) [29].
In the second experiment, samples from undiluted cancer cells from a CLL patient, 
harboring a heterozygous SF3B1-K700E missense transition substitution were analyzed. A 
diluted sample (1:103) was also generated by mixing this patient’s CLL DNA with wild-type 
genomic DNA from a healthy donor. The mutated SF3B1 locus in these samples, in addition 
to un-mutated genomic DNA from 18 healthy, volunteered individuals were sequenced at a 
mean depth of 620,000×.
For both experiments, each cell line dilution and patient sample was bar-coded and targeted 
with amplicon multiplexed sequencing using the Illumina MiSeq (2 × 150 bp) (Genewiz, 
South Plainfield, NJ). The number of raw sequence reads per samples depended on the 
utilized instrument. With sufficient DNA (in the form of PCR products or un-amplified 
genomic DNA), Illumina MiSeq could produce eight million paired-end 150 bp reads [15]. 
The primers were designed so that the paired-end reads substantially overlapped with each 
other and each read pair was merged to correct sequencing errors. The merged reads were 
mapped to the human reference genome (hg19) using the Burrows-Wheeler Aligner (BWA) 
alignment tool [26], and all variable sites were identified using an inclusive variant caller 
[11]. Raw sequence data are available at the Sequence Read Archive under Bio Project 
PRJNA421179.
4 Results
Simulated data
We generated a set of in silico experiments with exponentially expanded populations starting 
from a single, homogenous, 100 base-long sequence of binary bases. Each population was 
aggregated from four expansions that followed error rates of 10−3, 10−4, 10−5, and 10−6 
substitutions per site per cycle. The number 12, 14, and 18 of cycles were chosen to produce 
populations with 16,384, 65,536 and 1,048,576 total reads respectively. Each experiment 
contained 50 independent populations (S = 50) and for each experiment, D(v), the expected 
number of variants with depth v was calculated using equations (3). This experiment was 
repeated 100 times. Figure 1 shows the results, as well as statistically significant χ2 p values 
indicating high accuracy of the estimates from both the beta-binomial model and its NB 
approximation.
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Dilution experiments
We removed the real diluted TP53 mutation from cell line sequencing data, and arranged the 
erroneous variants based on their depth in 5×-sized bins. We then counted the number of 
variants Xb in each bin, and calculated D(v) using equation (4). Figures 2, 3, and 4 show the 
results for sequencing depths of 10K×, 100K×, and 1M×, indicating statistically significant 
χ2 p values that show a strong concordance between estimates from the beta-binomial 
model, its NB approximation, and ultra-deep sequencing data. Distinguishing transitions and 
transversions further clarified the importance of classifying variants using sequencing depth 
as a proxy for the error rates. We obtain similar results from modeling the ultra-deep 
sequencing data from the SF3B1 locus (Figure 5).
Detecting true mutations
We propose two comprehensive approaches to assess the presence of true mutations at very 
low abundance relative to background. Our methodology does not require matched normal 
samples or extensive filtering based on variant annotation resources.
First, having established an accurate model to describe the sequencing error distribution, a 
threshold is determined above which sequencing errors happen with a probability below an 
established statistical cut-off. These thresholds can be derived from all variants or a subset of 
variants, for example, only transitions or transversions. Figure 6 shows such thresholds for 
detecting the TP53-Y234C transition mutation in dilution experiments, where we are able to 
identify the mutation in abundances as low as 5:104 at 10K× and 100K×, and 1:104 at 1M×, 
without any false positive calls. As shown in Figures 2, 3, and 4, there is better sensitivity for 
detecting a transversion substitution.
In the absence of matched normal samples, this approach is especially practical for 
identifying mutations that may exist in more than one tumor sample. Its application to 309 
newly diagnosed CLL patients identified small sub-clonal prognostic mutations in four 
frequently mutated drivers of this neoplasm, present in 2 out of 1,000 wild-type alleles. 
These mutations were missed by traditional Sanger sequencing, but were validated by 
independent deep sequencing and allele-specific PCR [41,40].
Second, we tested an individual mutation in each sample against all other sequenced samples 
and calculated the cumulative P using equation (1). After correcting for multiple hypotheses 
using the Benjamini and Hochberg method [1], we generated a list of variants that satisfied a 
pre-determined false discovery rate. This approach is particularly powerful in identifying 
patient-specific mutations. We assess the presence of the SF3B1-K700E mutation in patient 
samples, and find the probability of observing the mutation in 1:103 CLL dilution to be 
extremely significant compared to controls (Table 1). This approach can accurately identify 
sample-specific mutations by comparing multiple samples at the same exact mutated base.
In comparison of our method to other published variant calling algorithms, one comparable 
unbiased method is EBCall, whose implementation is based on beta-binomial distributions 
and establishing priors from normal sequencing data [43]. EBCall requires normal samples; 
therefore, we removed the reads harboring the diluted mutations in the EBCall analysis to 
simulate matched normal data. EBCall, with a sensitivity-adjusted configuration, 
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successfully identified the SF3B1-K700E mutation in 1:103 CLL dilution sample, as well as 
the TP53-Y234C mutation in the least diluted samples at all sequencing depths (i.e. 1:10 in 
10K×, 1:102 in 100K×, and 1:103 in 1M×). However, it failed to detect the mutation at 
higher dilution levels, and also resulted in four false positive calls at 1M×.
5 Conclusion
Therapeutic resistance, one of the main causes of eventual disease relapse and mortality in 
cancer patients, is often associated with natural selection of preexisting resistant clones 
under treatment [13,41]. The detection of such low frequency sub-clones is hindered by a 
lack of precision-tested diagnostic assays.
Allele-specific, real-time PCR assays have been proposed to identify prognostic variants 
[31,18,49]. These approaches only target known mutations, and their adaptation to situations 
with large numbers of variants requires extensive primer calibration. In contrast, high-
throughput sequencing provides an unbiased view of tumor heterogeneity and its genomic 
profile. Various techniques based on unique molecular identifiers have been proposed to 
correct both polymerase and sequencing errors [22,19,17,37] that facilitate distinguishing 
real mutations from mistakes that arise during amplification. However, the main hurdle in 
clinical utilization of these approached is the requirement for generating very large numbers 
of sequencing reads to assemble the genome of a single DNA molecule with high confidence 
at depth > 2,000×.
Here, we addressed this important problem in cancer therapy by introducing a highly 
sensitive method to model sequencing noise, which allows the detection of prognostic 
markers of disease recurrence using ultra-deep targeted sequencing. Our approach is based 
on interrogating data from multiple tumor samples at identical genomic regions and provides 
an accurate assessment of the error rate at a given position without relying on normal 
samples. Instead of establishing a fixed detection threshold for all variants, we directly 
calculate mutation-specific sensitivities. Overall, since ultra-deep sequencing methods are 
now routinely implemented in the clinic, we believe that the application of our 
comprehensive model to tumor samples will increase the speed with which patients can be 
evaluated during disease surveillance. Our method opens up the possibility of exploring the 
dynamics of cancer clones after treatment, timing the rise of resistance to therapy, and 
determining the clinical importance of minimal residual disease assessed from liquid biopsy 
samples for precise disease management [16,45].
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Fig. 1. 
Number of variants with error depth of v from aggregated simulated cycles of PCR 
amplification at four error rates: 12 cycles (left), 14 cycles (middle), and 18 cycles (right). 
Ptheo. and NBtheo. are calculated using equation (3), and Pemp. and NBemp. are calculates 
using equation (4). The χ2 test was used to compare the distributions.
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Fig. 2. 
Error depth distribution in ultra-deep sequencing of a TP53 locus at 10,000× for all variants 
(left), transitions (middle), and transversions (right).
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Fig. 3. 
Error depth distribution in ultra-deep sequencing of a TP53 locus at 100,000× for all variants 
(left), transitions (middle), and transversions (right).
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Fig. 4. 
Error depth distribution in ultra-deep sequencing of a TP53 locus at 1,000,000× for all 
variants (left), transitions (middle), and transversions (right).
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Fig. 5. 
Error depth distribution in ultra-deep sequencing of a SF3B1 locus at mean 620,000× for all 
variants (left), transitions (middle), and transversions (right).
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Fig. 6. 
Sensitivity of detecting TP53-Y234C mutation dilutions. Assessing the presence of a variant 
requires correcting for multiple hypotheses based on the number of sequenced genomic 
positions (Bonferroni correction). Testing the presence of a discovered variant does not 
require such a correction; here, significance is set at 0.01.
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